Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8354161 | 0.98 | — | — | |
| SCHEMBL5009996 | 0.98 | — | — | |
| SCHEMBL19815561 | 0.76 | — | — | |
| SCHEMBL19815966 | 0.76 | — | — | |
| SCHEMBL7141789 | 0.74 | — | — | |
| SCHEMBL17180449 | 0.72 | CYP2D6 (0.37) | — | |
| SCHEMBL9733206 | 0.65 | CTSC (0.32) | — | |
| Hydrochloric Acid SCHEMBL19815662 | 0.65 | — | — | |
| Hydrochloric Acid SCHEMBL17709754 | 0.64 | — | — | |
| Hydrochloric Acid SCHEMBL17709753 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250135043-A1 | DUAL-TARGETING COMPOUND FOR FIBROBLAST ACTIVATION PROTEIN (FAP) AND INTEGRIN avB3, PREPARATION METHOD THEREFOR AND USE THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO., LTD. (CN) | 2025-05-01 | — | — | US | claimed |
| WO-2024067531-A1 | DUAL-TARGETING COMPOUND AGAINST FIBROBLAST ACTIVATION PROTEIN FAP AND INTEGRIN αVβ3, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 烟台蓝纳成生物技术有限公司 | 2024-04-04 | — | — | WO | claimed |
| CN-116751259-A | Fibroblast activation protein FAP and integrin alpha v β 3 Dual targeting compounds and methods of making the same | 烟台蓝纳成生物技术有限公司 | 2023-09-15 | — | — | CN | claimed |
| CN-115260160-B | Compound of targeted fibroblast activation protein FAP, preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-115505032-A | Fibroblast activation protein FAP and integrin alpha v β 3 Dual-targeting compound and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2022-12-23 | — | — | CN | claimed |
| CN-115260160-A | Compound of targeted fibroblast activation protein FAP and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2022-11-01 | — | — | CN | claimed |
| EP-4711362-A1 | LIGAND TARGETING FIBROBLAST ACTIVATION PROTEIN | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-03-18 | — | — | EP | disclosed |
| EP-4674847-A1 | NOVEL SCAFFOLD 99MTC-FAPI DIAGNOSTIC PROBE AND USE THEREOF IN PREPARATION OF DRUG OR REAGENT FOR DIAGNOSING TUMOR | Nanjing Nuoyuan Medical Instrument Co., Ltd (CN) | 2026-01-07 | — | — | EP | disclosed |
| US-12473285-B2 | DCN-1 modulating compounds and methods of use thereof | CELLARITY, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250257063-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-08-14 | — | — | US | disclosed |
| US-20250177582-A1 | HIGH-AFFINITY LIGANDS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2025-06-05 | — | — | US | disclosed |
| US-20250163057-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-05-22 | — | — | US | disclosed |
| WO-2025096956-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | CELLARITY, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-7291618-B2 | Therapeutic compounds | PFIZER INC (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2007-07-12 | — | — | US | disclosed |
| US-20070099897-A1 | Therapeutic compounds | PFIZER INC | 2007-05-03 | — | — | US | disclosed |
| EP-1753748-A1 | PROLINE DERIVATIVES AND THEIR USE AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | Pfizer Products Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060079498-A1 | Therapeutic compounds | PFIZER INC | 2006-04-13 | — | — | US | disclosed |
| WO-2005116014-A1 | PROLINE DERIVATIVES AND THEIR USE AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050256310-A1 | Therapeutic compounds | PFIZER INC | 2005-11-17 | — | — | US | disclosed |